Tower Research Capital (TRC)’s Acrivon Therapeutics ACRV Stock Holding History

Tower Research Capital (TRC)’s Portfolio ACRV Stock Details ACRV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$6.29K	Buy	+4,526	New	+$7.89K	﹤0.01%	4064
2025 Q4	–	Sell	-8,736	Closed	-$15.8K	–	5114
2025 Q3	$15.8K	Sell	8,736 -108	-1%	-$152	﹤0.01%	3518
2025 Q2	$10.5K	Buy	8,844 +5,754	+186%	+$7.9K	﹤0.01%	3944
2025 Q1	$6.27K	Buy	3,090 +1,324	+75%	+$7.13K	﹤0.01%	4055
2024 Q4	$10.6K	Sell	1,766 -2,989	-63%	-$21.7K	﹤0.01%	3789
2024 Q3	$33.3K	Buy	4,755 +976	+26%	+$7.69K	﹤0.01%	2947
2024 Q2	$21.9K	Buy	3,779 +2,962	+363%	+$23.9K	﹤0.01%	3705
2024 Q1	$5.84K	Sell	817 -1,201	-60%	-$5.58K	﹤0.01%	4481
2023 Q4	$9.93K	Buy	2,018 +763	+61%	+$4.03K	﹤0.01%	4326
2023 Q3	$12K	Buy	1,255 +523	+71%	+$6.04K	﹤0.01%	3936
2023 Q2	$9.49K	Sell	732 -360	-33%	-$4.36K	﹤0.01%	4274
2023 Q1	$14K	Buy	1,092 +933	+587%	+$15.7K	﹤0.01%	3856
2022 Q4	$2K	Buy	+159	New	+$2.02K	﹤0.01%	5315

Other funds holding ACRV

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

SCV

Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Tower Research Capital (TRC)'s ACRV Position: Q1 2026 in Review

Tower Research Capital (TRC) opened a new position in Acrivon Therapeutics (ACRV) in Q1 2026: 4,526 shares worth $6.29K. The stake represents ﹤0.01% of the portfolio and ranks #4064 among its holdings. This is a return to the name: Tower Research Capital (TRC) previously reported a position in ACRV as recently as Q3 2025.

Tower Research Capital (TRC) first reported a position in ACRV in Q4 2022 and has held it in 13 quarters since. The position peaked at $33.3K in Q3 2024. 44 funds tracked by Wall St. Rank hold ACRV as of Q1 2026.

Tower Research Capital (TRC) held 4,526 shares of Acrivon Therapeutics worth $6.29K as of Q1 2026.
Acrivon Therapeutics was a new Tower Research Capital (TRC) position in Q1 2026.
Acrivon Therapeutics made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #4064 holding.
Tower Research Capital (TRC) first reported a position in Acrivon Therapeutics in Q4 2022 and has held it in 13 quarters since.
Tower Research Capital (TRC)'s Acrivon Therapeutics position peaked at $33.3K in Q3 2024.
44 funds tracked by Wall St. Rank held Acrivon Therapeutics as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.